New-onset seizures in older people: Clinical features, course and outcomes

• DOI: 10.1016/j.jns.2021.118065
• Publication Date: 2021-09-02T14:56:56Z
• Authors: Sebastian F. Green; Nadine Loefflad; Dominic C. Heaney; Sanjeev Rajakulen...
• Keywords: Epilepsy; Epilepsies; Seizure; 3. Good health; Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; Seizures; Humans; Epilepsies, Partial; Older people; Anti-seizure medication; Partial; Aged; Retrospective Studies

The incidence of epilepsy increases with age. With current demographic trends, this presents a healthcare challenge. We investigated the clinical spectrum of first seizures, evaluated neuroimaging and EEG findings, and determined clinical outcomes, including anti-seizure medication (ASM) response in older people. In addition, we sought to understand the relative effects of age and frailty on ASM response.A retrospective single centre cohort study of 207 cases ≥60 years' old, 113 of whom were eventually diagnosed with a first seizure in a specialist epilepsy clinic.65/113 (57.5%) presented with either focal aware or focal impaired awareness seizures. Stroke was the most common aetiological association (31.9%, 36/113), and odds of seizure recurrence did not significantly differ between aetiologies. 55/86 (64.0%) who started an ASM had no seizure recurrence. 14/48 (29.2%) who underwent EEG had epileptiform abnormalities, however EEG result directly affected management in only 4/48 (8.3%). The most common MRI findings were small vessel disease (37/93, 39.8%), stroke (27/93, 29.0%) and global atrophy (14/93, 15.1%). Increasing age and frailty did not affect the odds of seizure recurrence or of experiencing ASM side effects. Severity of small vessel disease or atrophy did not affect odds of seizure recurrence.Our data inform the management of first seizures in older people and provisionally support the use of ASMs in patients with increasing age and frailty, despite concerns over polypharmacy and comorbidity. Our findings should be replicated in larger cohorts.